Greg B. Scott - President and Founder, ChinaBio® LLC
Greg is an entrepreneur, angel investor and business advisor who has helped launch over thirty life science companies in the U.S. and China. He founded ChinaBio® LLC in January 2007 to identify and develop early stage life science companies in China and has helped raise over $350M in government and VC funding. ChinaBio also works with U.S. and European companies seeking partners, acquisitions and novel technologies in China. ChinaBio has organized ten investment conferences in China in just three years, and will hold its third annual ChinaBio Partnering Forum in Beijing in May, 2011. This international event will draw over 600 attendees from around the globe. Greg is also the president and co-founder of Life Science Angels, an angel investment group that has funded 32 biotechnology and medical device companies in the U.S. and China since 2005, and Executive Editor of the ChinaBio® Today newsletter. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was co-founder of a 200-person consulting firm. Greg lives and works in Shanghai but visits the U.S. several times a year to enjoy California’s blue sky and sandy beaches.
Leon Chen, PhD - Partner, Fidelity Asia Ventures
Dr. Leon Chen joined Fidelity Asia Ventures in 2008 with over 15 years of experience as an accomplished scientist, management consultant and venture capitalist. Prior to joining FAV, Leon was a Managing Partner at BioVeda China and had led a number of investments in the life science sector in China including Cathay Industrial Biotechnology and CITIC Pharmaceuticals. From 1997 to 2005, Leon was a management consultant and a business adviser to Pharmaceutical and Biotech companies. He worked as a management consultant with McKinsey & Company, Ernst& Young LLP, and as a co-founder and Managing Partner with Life Science Strategic Consulting in the San Francisco Bay Area.From 1993 to 1997, Leon worked as a research scientist at Schering-Plough in New Jersey. He was a member of the discovery team of "VYTORIN"/"ZETIA" –now a multibillion dollar drug. He received a BS degree from Peking University, a PhD degree with top honor in Organic Chemistry from Catholic University of Louvain, and was a Post-Doc Fellow at the Massachusetts Institute of Technology. Leon holds 6 issued US Patents and co-authored the 14th and 15th Ernst & Young Biotechnology Report.
Dr. Peng Chen is a partner in the Business Department’s Patent Group of Morrison & Foerster’s San Diego office. His practice focuses on patent prosecution, counseling and litigation, encompassing all fields of the biotechnology, pharmaceutical and diagnostic industries. He received his JD from Columbia University, undergraduate degree in biochemistry from the Beijing Normal University, and PhD from Johns Hopkins University School of Medicine. Recently, Dr. Chen was selected by his peers as one of the The Best Lawyers in America for Biotechnology Law and IP Law. He was also ranked as a leading lawyer in patent licensing by Legal 500 United States®. Dr. Chen is admitted to practice in California and New York, and is registered to practice before the U.S. Patent and Trademark Office.
Francine Fang, MD, PhD - Senior Consultant, TusPark Ventures
Francine Fang is a Senior Advisor of Tuspark Venture which has portfolio companies in the areas of drug discovery, preclinical CRO, in vitro diagnostic and medical software. She is also CEO of BioStar, a consulting service company focusing mostly on early stage healthcare investments. As a senior advisor for Beijing Municipal Government, she has consulted a CMO co-investment by Beijing government and foreign VC and many other cases. Francine Fang got her MD from Capital Medical University, and PhD from University of Medicine and Dentistry of New Jersey. She was a scientist in R&D at Clontech in molecular and cell biology. Francine Fang held management positions at BD Biosciences where she has worked for nearly 10 years.
Alex Fowkes, JD - Executive Director, Head of R&D Business Development, Pfizer Global Research & Development
Mr. Alex Fowkes obtained undergraduate degrees in science and law in Australia before joining a private practice law firm in 1994. In 1998, Alex joined Pfizer’s operations in the United Kingdom to provide legal support to its European research and development activities. In 2003, Alex moved to the Pfizer Research and Development Division (PGRD) headquarters in New London, Connecticut to lead the global legal support for PGRD’s world-wide technology transfer activities. At the end of 2006, Alex was appointed to lead PGRD’s Strategic Alliance operations in Asia and relocated to Pfizer’s Research Office in Shanghai.
Jian Han, MD, PhD - President & CSO, iCubate Inc.
Dr. Jian Han is a Faculty Investigator at HudsonAlpha Institute for Biotechnology. He is the founder of Genaco, Diatherix, iCubate, and iRepertoire. In 1996, he founded Genaco, raised $2.5 million from angel investors and was the first to introduce Down's Syndrome prenatal screening and diagnosis technology to China. The product won SDA approval and later transferred to FDZJ. He is also responsible to introduce Luminex technology to China, drafted the national standard and got it approved by the SDA as a medical device. In 2003, during the SARS outbreak, he invented a multiplex PCR technology called tem-PCR and developed a multiplexed PCR assay that detecting 10 common respiratory pathogens with one test. The technology won Genaco Frost & Sullivan Technology and Innovation Award (06) and Wall Street Journal Technology Innovation award (07, runner up). The technology and his company were acquired by Qiagen for $40 million. In 2008, Dr. Han invented the next generation of multiplex PCR technology, arm-PCR, and developed a fully integrated instrument platform, iCubate. He graduated from Suzhou Medical College and obtained his PhD in Medical Genetics at the University of Alabama at Birmingham.
Jennifer Hu, PhD - Director of Licensing & External Research, Merck & Co., Inc., USA
Dr. Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan) at Merck & Co., Inc., USA. She is responsible for identifying, evaluating, and developing opportunities related to partnership, licensing-in, and acquisition for new drug candidates and technologies for drug discovery and development in Mainland China, Hong Kong, and Taiwan. Prior to joining Merck & Co., Inc. in early 2008, Dr. Hu worked with Roche Pharmaceuticals at Palo Alto as Research Leader and Head of Functional Biology following serving as the Program Leader for Toxicogenomics since 2004. Prior to that, she worked at Affymetrix in various capacities, including as Program Manager of Toxicology/Pharmacogenomics, establishing and managing programs with both pharmaceutical and academic partners to develop and demonstrate the application of Affymetrix GeneChip technology. She started her career at Human Genome Sciences as one of the founding scientists and Project Leader of VEGF-2 Protein Therapeutics program. Dr. Hu got her BS degree in Biochemistry from Peking University; PhD from Univ. of Texas & M.D. Anderson Cancer Center through CUSBEA program; her post-doctoral training at Harvard Medical School. She has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications. She has served as the 2006-2007 President of Sino-American Pharmaceutical Professionals Association – West (SAPA-West) and the 2002-2003 Chairperson of the Board of Peking University Alumni Association of Northern California (PKUAANC). Dr. Hu has 17 years of research, management, & business development experience with US biotech and pharmaceutical industry.
Kewen Jin, PhD - General Manager, Charles River Greater China
Dr. Kewen Jin is currently General Manager of Charles River Laboratories (CRL) China preclinical service company. He was founder/CEO of BioExplorer, a preclinical CRO which formed a JV with CRL in 2007. Kewen has co-founded and served as key executive (CEO, CBO, and founding partner) for three other companies in the R&D outsourcing, drug discovery, and consulting. He served as advisor to several MNC pharma and healthcare companies, major consulting and investment firms. Previously, he was a marketing and international operation executive with Wyeth, first five years in the U.S. , then two years in Beijing. He is a Senior Advisor to Shanghai Pudong Government. He was granted the 2005 Magnolia Award, which the Shanghai government grants to individuals making major contribution to the development of Shanghai. He is a member of the Board of Directors for Bayhelix and Sino American Pharmaceutical Association (SAPA), two leading Chinese life science professional organizations. He was trained in medicine (Shanghai Jiaotong University School of Medicine), biology (Rockefeller), finance (Columbia).
Karen Liu, PhD - VP, China Renaissance Capital Investment
Dr. Karen Liu has worked in China for over 12 years; Her past experiences include management consulting at McKinsey & Company and a successful entrepreneurship helping to build up one of the leading Internet company in China and eventually sold the company to Yahoo; Dr. Liu had also been an active angel investor in the biotechnology sector. She is a founder and angel investor for Shenogen Pharma Group, a new drug development venture with a promising pipeline of anti-cancer drugs. Dr. Liu is currently an investment director at CRCI Capital, a premier China based VC and PE investment firm. She focuses on investing in the life science and biomedical sector and her past investment experience include sectors such as medical device, drug development, industrial biotech, specialty pharma, CRO as well as pharmaceutical fine chemical. Dr. Liu has a PhD in Immunology from Harvard University and BS in Biochemistry from Cornell University.
Yuwen Liu, MBA - Chairwoman & CEO, BioBay
Liu Yuwen received her Master’s degree from China Pharmaceutical University and her MBA from Fudan University, China and Norwegian Management School. She is also a licensed pharmacist. She started her career with Capsugel®, a division of Pfizer in Suzhou, China as a quality engineer in 1997 and was promoted to QA manager in April 1998. In May 2000, following the strategic expansion of Capsugel China, she transferred to the new Business Development department where she managed market opportunities in the great China region. In May 2003, she moved to Shanghai as General Manager to set up the representative office for Perrigo Company (the world’s largest manufacturer of OTC pharmaceutical and nutritional products for the store brand market). While in Shanghai, she also took charge of all related market development activities including JV’s in China as well as supply management in other Asia Pacific regions such as Japan, Korea, Taiwan etc. In Dec. 2005, she moved back to Suzhou as executive vice president for BioBay, a bio science park funded by the Suzhou Industrial Park, whose mission is to build an integrated comprehensive platform for biotech, pharmaceutical and nanotech research and development in China. In August, 2007, she became the general manager of BioBay, vice president of Suzhou Ventures Group, and assistant director of Suzhou Industrial Park Science & Technology Bureau. In June, 2010 she became Chairwoman and CEO of BioBay.
Peter (Peizhi) Luo, PhD - Founder & Chairman, Adagene Inc.
Dr. Peter Luo is a serial entrepreneur with proven track record in innovative technology and product development. Peter was the Director of Biologics at Merck & Co., Inc. and Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co and was responsible for building Merck antibody phage libraries and engineering platform as the discovery engine for Merck novel biologics. Prior to the acquisition of Abmaxis by Merck in 2006, Peter was the Cofounder, Chief Technology Officer, President and the Board Directors of Abmaxis Inc, and played a key role in building Abmaxis management and scientific team and shaping its technology and business strategies. Peter was the first lead scientist in Xencor in computational protein design and protein laboratory. He did his postdoctoral research in protein folding at Stanford University. He received his PhD in Chemistry from The University of Chicago, a MS degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and a BS degree in chemistry from Peking University.
Jie Mi, PhD, MBA - Vice President of Investments, Goldstone Investment Co.
Dr. Jie Mi is Vice President of Investments at Goldstone Investment Co., a fully-owned subsidiary of CITICS, a leading investment bank in China. Her investment focus is in the sectors of healthcare, lifesciences, biotechnology, and pharmaceutics. Dr. Mi has joined Goldstone returning from US venture capital field, where she managed an investment portfolio of more than eighty early to mid-stage projects of life sciences and healthcare. Prior to investment and fund management career, Dr. Mi was a serial entrepreneur and investigator/inventor in biotechnology. Dr. Mi receives a BS in Genetics from Peking University, a MBA from University of Washington, Seattle, a PhD in Virology from Medical College of Wisconsin, and postdoctoral training at UCLA Brain Research Institute and University of Washington Medical School.
Joshua Ning, MBA - President & CEO, Suzhou DingMind Co., Ltd.
Mr. Joshua Ning is President and CEO with Suzhou DingMind Co., Ltd., which is a medical device start-up company focusing on advanced neurological diagnostic and therapeutic products. Prior to his current position, Mr. Ning had held multiple positions in multi-national companies, GE healthcare, Becton Dickinson & company, Medtronic, Siemens and Dentsply, as Engineer, Sales Manager，Marketing Manager, Business Director and General Manager. Mr. Ning is one of the first generation graduations of Biomedical engineering in China. He has engaged in China medical device market for 20 years. Mr. Ning received BS in Biomedical Engineering and Master of Medicine in Biophysics from FuDan University, EMBA from Cheung Kong Graduate School of Business.
Marc A. Schueler, MD, PhD, MBA - Director Venturing, DSM
Dr. Marc Schueler has been active in Venture Capital for more than 10 years investing in more than 40 companies and VC funds worldwide generating an overall IRR of 26%. He was a partner in 4 VC funds with a combined raised capital of more than US$ 500 million and is since 2009 located in Beijing to set-up a new Investment Vehicle for China for the Dutch Life & Material Sciences Company DSM, whose global Venture Capital program he had build up in the last 6 years. Previously he held Senior Executive Positions at Procter& Gamble and McKinsey in Europe and the USA. He is a MD graduate and qualified Eye Surgeon from the University of Heidelberg and holds a PhD from the University of Freiburg in immunology and internal medicine as well as a MBA from the University of Bradford, UK, with a specialisation in Finance.
Victor Shi, PhD - President, Asia Pacific, QIAGEN
Dr. Victor Shi is Asia Pacific President of QIAGEN, a publicly-listed world leading provider of sample and assay technologies in the field of molecular diagnostics. Dr. Shi heads QIAGEN’s commercial operations and strategic development in Asia and manages an organization with over 500 employees in 11 subsidiaries. Dr. Shi has over 17 years’ experience in life science business development, management and investment. Previously held positions include Managing Partner, Aura Partners (Shanghai and Hong Kong), Senior Vice President of Corporate Development, Bridge Pharmaceuticals (Menlo Park, California), Managing Director of Discovery Resources Group (Palo Alto, California), Vice President of Corporate Development at Genospectra (Fremont, California), and Director of Asia Operations at A. M. Pappas & Associates (Singapore). He was also a faculty member at National University of Singapore School of Medicine and a cancer research scientist at Merck & Co. Dr. Shi holds PhD and MS degrees from the University of Rochester, New York, and a B.S. degree from the University of Science and Technology of China.
Timothy Wong, PhD - Marketing Development Manager, Drug Discovery, Pharma and CRO, Asia Pacific Invitrogen, by Life Technologies
Dr. Timothy Wong is the Asia Pacific Market Development Manager for Pharma and CRO sectors in Invitrogen, part of Life Technologies. He also holds business management responsibility in Invitrogen supporting drug discovery and development needs in Asia Pacific. He has been with Invitrogen and previously Life Technologies/GibcoBRL since 2000. Currently, apart from building Invitrogen’s drug discovery and development business in Asia Pacific, his role is to strategize partnership/collaboration model with pharmaceutical industry, CRO and research institutes to facilitate drug discovery research in Asia Pacific. Previously, he was responsible for Invitrogen technical services and marketing communication in Pacific regions while facilitating development of proteomic research in Asia by connecting Invitrogen resources to Human Proteomic Organization and the local scientific communities. Dr. Timothy Wong received his BSc (Hons) in Biology at The Hong Kong University of Sciences & Technologies. Dr. Wong received his PhD in Biochemistry at Chinese University of Hong Kong with focus on identifying drug resistance mechanism and improving cancer drug efficacy in multidrug resistance cancer cells. Dr. Wong has received American Association for Cancer Research (AACR) Young Investigator Award.
Chun Wu, PhD - Founder & CEO, Abgent (San Diego, CA) and Abgent Biotechnology (Suzhou) Co.
Dr. Chun Wu is the founder and CEO of Abgent (San Diego, CA) and Abgent Biotechnology (Suzhou) Co. Abgent develops powerful research tools to profile posttranslational modifications that related to cellular function and disease. Abgent's over 10,000 innovative research products and custom services rank it as a selected supplier in “Nature” from 2003-2006 and in “The Scientist” 2003 and 2004 Features. Dr. Wu has over twenty years of industrial experience with excellent record in research and development of molecular and immunological research tools. Prior to Abgent, Dr. Wu was a co-founder of Imgenex (San Diego, CA). He was also a scientist at BD (PharMingen) and New England Biolabs. Dr. Wu received a PhD degree in neurobiology from the University of Manchester, UK and he is a graduate of Hunan Medical University (now Xiangya Medical School of Central South University), China.
Bai Xu, PhD - President & CEO, Suzhou Natong Nanobiotechnology Co., Ltd.
Graduated from University of Paris, The Molecular Materials Lab of National Center of Scientific Research, France, Dr. Xu’s professional activity focuses mainly on the development of micro-electro-mechanical systems, popularly known as MEMS. MEMS technology is the integration of sensors, actuators, together with electronics on single silicon chip or other substrate to enable a dramatic improvement in system performance. Dr. Xu was SEMI task force leader and co-leader for MEMS fluidic interface standards. He also served at the Editorial Board of “Nanomedicine: Nanotechnology, Biology and Medicine”. Before he devoted his full effort to Suzhou Natong, an intraepidermal drug repositioning company he co-founded, he was a founding faculty of world’s first college exclusively dedicated to nanotechnology research and education: College of Nanoscale Science and Technology (CNSE) at University at Albany. He served as Senator in CNSE Faculty Senate and committee members of CNSE Curriculum Committee, Qualifying Exam Committee, Faculty and Professional Staff Search Committee.
David Xu, PhD, MBA - Managing Partner, Mingly China Growth Fund
David Xu is the Managing Partner of Mingly China Growth Fund. David has over 10 years of investment banking experience in China. Previously, David worked at EBICC, Create Capital, China Fortune Securities and Goldman Sachs. He also worked as a research fellow at Columbia Medical Center for 7 years. David received his BS degree from University of Science & Technology of China, PhD in Microbiology from Columbia University, and MBA from MIT Sloan School of Management.
Stella Xu, PhD - Executive Director, Roche Global Pharma Partnering
Dr. Stella Xu is the Executive Director with Roche Global Pharma Partnering. Her major responsibilities include searching potential licensing opportunities (products / technologies), and supporting transaction discussions & alliance management with Asian partners. Prior to her current position, Stella had held multiple global positions in Roche Pharma Partnering and led more than 30 product-focused due diligence projects and alliances such as Toyama, Japan Tobacco, and Maxygen. Stella joined Roche from McKinsey & Company, a management consulting firm that provides strategic advices to the top management of global business leaders. At McKinsey, she led consulting engagements with biopharmaceutical clients in areas ranging from R&D strategy, marketing & sales, to corporate development and M&A activities. Prior to McKinsey, Stella was a research scientist with Isis Pharmaceuticals. Stella received her B.S. in Biophysics from Peking University; her PhD in Biochemistry, Molecular Biology and Cell Biology from Northwestern University.
Yanning Yi, MBA - Executive Director, The Balloch Group
Yanning Yi joined TBG in 2007 and focuses on the firm's investment banking practices in the healthcare sector. Mr. Yi has worked with the healthcare team of CIBC World Markets originating IPO transactions in the US and has extensive experience on private equity deals for CRO, specialty pharma, drug discovery, and medical device companies. Prior to joining TBG, Mr. Yi worked at CIBC in Toronto where he focused on credit and investment portfolio risk management. Prior to that, Mr. Yi spent seven years with China's largest policy bank, China Development Bank, where he completed debt transactions totaling more than $3 billion in the energy, mining, manufacturing, and infrastructure industries. Mr. Yi received his MBA from the University of Western Ontario, Canada and his BA in Economics from the China Institute of Finance and Banking.
Jason Zhao, MBA - Investment Director, SB China Venture Capital
Mr. Jason Zhao joined SB China Venture Capital (SBCVC) in 2006. In the last four years, he mostly focused on healthcare related investment opportunities, such as Chemclin, EDAN and Di’An Diagnosis etc. Mr. Zhao also explored investment opportunities in IT, clean tech and other high tech fields. Prior to joining SBCVC, he was with China Galaxy Securities Ltd Co., where he worked on the process of several IPO projects in A-share market. Mr. Zhao had also worked in Beijing Haidian Hospital for three years since 1999, serving as a doctor in general surgical department. Mr. Zhao holds a MBA from Economic and Management College of Tsinghua University, Bachelor Degree of Clinical Medical from Beijing Medical University.